Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
With the advent of advances in biomarker detection and neuropsychological measurement, prospects have improved for identifying and tracking the progression of Alzheimer's disease (AD) from its earliest stages through dementia. While new diagnostic techniques have exciting implications for initiating treatment earlier in the disease process, much work remains to be done to optimize the contributions of the expanding range of tools at the disposal of researchers and clinicians. The present paper examines recent work in cerebrospinal fluid biomarkers, magnetic resonance imaging, positron emission tomography, neuropsychological measures, and functional assessment. The strengths and weaknesses of current methodologies are explored and discussed. It is concluded that AD from its mild cognitive impairment state through dementia represents a continuous process, and that progression over time can best be accomplished by interval-level variables. Biomarkers that are most sensitive to early AD may not be the most optimal for monitoring longitudinal change, and it is likely that multivariate models incorporating cognitive measures, functional variables and biomarker data will be the most fruitful avenues for future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986 · cited 3×
“Signifi cant percentages of cognitively normal older people may have AD pathology but do not manifest cognitive symptoms during life [69], and many cases of MCI have non-AD pathology.”
Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 1×
“Th e CSF Aβ-42/tau ratio diff erentiated patients with subjective cognitive complaints, with non-aMCI, and with aMCI from healthy controls [46], was predictive of progression from aMCI to AD [46], was predictive of progression from controls to MCI [47], predicted cognitive decline in cognitively normal older adults [4…”
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896
Cognitive Reserve and Alzheimer Disease
Stern, Y. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213815.20177.19 · Cited by 838 · cited 1×
“Another challenge in cognitive assessment is the issue of cognitive reserve [18], which allows persons with diseased brains to use compensatory mechanisms that may mask overt manifestations of disease.”
Quantification of Five Neuropsychological Approaches to Defining Mild Cognitive Impairment
Jak, A. J., Bondi, M. W., Delano-Wood, L., Wierenga, C., Corey-Bloom, J., Salmon, D. P., & Delis, D. C. (2009) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31819431d5 · Cited by 823
Comparing predictors of conversion and decline in mild cognitive impairment
Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., Jack, C. R., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e8e8b8 · Cited by 616
Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease
Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., DeCarli, C. S., Scott Turner, R., Koeppe, R. A., Higdon, R., et al. (2007) · Brain · doi:10.1093/brain/awm177 · Cited by 608 · cited 1×
“FDG-PET successfully identifi ed diff erent metabolic patterns in AD and cerebrovascular disease [81] and assisted in distinguishing between AD and frontotemporal dementia [82].”
Disruption of Functional Connectivity in Clinically Normal Older Adults Harboring Amyloid Burden
Hedden, T., Van Dijk, K. R. A., Becker, J. A., Mehta, A., Sperling, R. A., Johnson, K. A., & Buckner, R. L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3189-09.2009 · Cited by 598
Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.269 · Cited by 476
Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
De Meyer, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.179 · Cited by 462 · cited 1×
“Furthermore, 100% of subjects with MCI who progressed to AD and 94% of pathologically verifi ed AD patients could be identifi ed [57].”
Relationships between biomarkers in aging and dementia
Jagust, W. J., Landau, S. M., Shaw, L. M., Trojanowski, J. Q., Koeppe, R. A., Reiman, E. M., Foster, N. L., Petersen, R. C., Weiner, M. W., Price, J. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc010c · Cited by 456 · cited 1×
“CSF proteins predict the rate of cognitive decline in AD [52], in mild AD [53], and in healthy older adults [54].”
Imaging amyloid deposition in Lewy body diseases
Gomperts, S. N., Rentz, D. M., Moran, E., Becker, J. A., Locascio, J. J., Klunk, W. E., Mathis, C. A., Elmaleh, D. R., Shoup, T., Fischman, A. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000326146.60732.d6 · Cited by 443 · cited 1×
“Also, PiB uptake appears to be nonspecifi c for AD, as it has been shown to be elevated in Parkinson’s dementia [72] and in Lewy body disease [73].”
MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment
Whitwell, J. L., Shiung, M. M., Przybelski, S. A., Weigand, S. D., Knopman, D. S., Boeve, B. F., Petersen, R. C., & Jack, C. R. (2008) · Neurology · doi:10.1212/01.wnl.0000280575.77437.a2 · Cited by 357 · cited 2×
“Research has demonstrated changes in medial temporal lobe structures in subjects with MCI [83] or in subjects with aMCI who progress to dementia [84].”
Fagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353
Regional rates of neocortical atrophy from normal aging to early Alzheimer disease
McDonald, C. R., McEvoy, L. K., Gharapetian, L., Fennema-Notestine, C., Hagler, D. J., Holland, D., Koyama, A., Brewer, J. B., & Dale, A. M. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b16431 · Cited by 299
Rabin, L. A., Paré, N., Saykin, A. J., Brown, M. J., Wishart, H. A., Flashman, L. A., & Santulli, R. B. (2009) · Aging, Neuropsychology, and Cognition · doi:10.1080/13825580902825220 · Cited by 256
Mosconi, L., Mistur, R., Switalski, R., Brys, M., Glodzik, L., Rich, K., Pirraglia, E., Tsui, W., De Santi, S., & de Leon, M. J. (2009) · Neurology · doi:10.1212/01.wnl.0000333247.51383.43 · Cited by 188
Hutchinson, A. D., & Mathias, J. L. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.100669 · Cited by 187 · cited 1×
“Another meta-analysis comparing AD with fronto temporal dementia showed signifi cant diff erences between groups on multiple measures, but the consider able overlap between groups renders diff erential diag nosis in individual cases diffi cult [ 24 ].”
Ganguli, M., Chang, C.-C. H., Snitz, B. E., Saxton, J. A., Vanderbilt, J., & Lee, C.-W. (2010) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181cdee4f · Cited by 172
Trajectories of brain loss in aging and the development of cognitive impairment
Carlson, N. E., Moore, M. M., Dame, A., Howieson, D., Silbert, L. C., Quinn, J. F., & Kaye, J. A. (2008) · Neurology · doi:10.1212/01.wnl.0000280577.43413.d9 · Cited by 144 · cited 1×
“Similarly, Carlson and colleagues showed that rates of ventricular volume expansion are greater in subjects who go on to develop MCI, and that the rate of expansion increases in the 2 to 3 years prior to clinical MCI diagnosis [86].”
Langbaum, J. B. S., Chen, K., Caselli, R. J., Lee, W., Reschke, C., Bandy, D., Alexander, G. E., Burns, C. M., Kaszniak, A. W., Reeder, S. A., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.30 · Cited by 100
de Jong, D., Jansen, R. W. M. M., Kremer, B. P. H., & Verbeek, M. M. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.7.755 · Cited by 98 · cited 1×
“Th e CSF Aβ-42/tau ratio diff erentiated patients with subjective cognitive complaints, with non-aMCI, and with aMCI from healthy controls [46], was predictive of progression from aMCI to AD [46], was predictive of progression from controls to MCI [47], predicted cognitive decline in cognitively normal older adults [4…”
Stein, J., Luppa, M., Brähler, E., König, H.-H., & Riedel-Heller, S. G. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000289779 · Cited by 65 · cited 1×
“Techniques such as reliable change indices and consideration of practice eff ects are methods to measure meaningful change at an individual level, which can also be useful in analyzing the results of clinical trials [17].”
Ercoli, L., Siddarth, P., Huang, S.-C., Miller, K., Bookheimer, S. Y., Wright, B. C., Phelps, M. E., & Small, G. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.4.442 · Cited by 31 · cited 1×
“FDG-PET hypometabolism has been associated with amyloid burden [62], CSF biomarkers [74], maternal history of AD [75], apolipoprotein E4 status in healthy adults [76], verbal memory test decline [77], memory test performance [78], and perceived memory loss [ 79 ].”
Cited by
Neuroinflammatory Markers: Key Indicators in the Pathology of Neurodegenerative Diseases
Rauf, A., Badoni, H., Abu-Izneid, T., Olatunde, A., Rahman, M. M., Painuli, S., Semwal, P., Wilairatana, P., & Mubarak, M. S. (2022) · Molecules · doi:10.3390/molecules27103194 · Cited by 306
RetractedClinical features and multidisciplinary approaches to dementia care
MacDonald, S., Grand, & Caspar (2011) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s17773 · Cited by 254
Plasma microRNA biomarkers for detection of mild cognitive impairment
Sheinerman, K. S., Tsivinsky, V. G., Crawford, F., Mullan, M. J., Abdullah, L., & Umansky, S. R. (2012) · Aging · doi:10.18632/aging.100486 · Cited by 188
“Moreover, MCI is not a homogeneous pathology and is currently described as two clinical conditions - with amnestic symptoms (aMCI) and without amnestic symptoms [8,13].”
BackgroundTarnanas, I., Tsolaki, M., Nef, T., M. Müri, R., & Mosimann, U. P. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.002 · Cited by 77
Nasrouei, S., Rattel, J. A., Liedlgruber, M., Marksteiner, J., & Wilhelm, F. H. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.11.003 · Cited by 30
Metadata
- Authors
- Brooks, L. G., & Loewenstein, D. A.
- Venue
- Alzheimer's Research & Therapy
- Published
- 2010-09-29
- Volume
- 2
- Issue
- 5
- Pages
- 28-28
- ISSN
- 1758-9193 (ISSN-L)
- OpenAlex
- W2130386048
- Cited by
- 102
- References
- 29
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.